[Source: Trading Markets] – Capstone Therapeutics (Nasdaq: CAPS | Quote | Chart | News | PowerRating) announced today the completion of enrollment for its AZX100 Phase 2 clinical trial in dermal scarring following shoulder surgery.
The clinical trial is a Phase 2a double blind, placebo controlled, multi-center dose ranging study to evaluate the safety and preliminary efficacy of AZX100 in trocar sites of arthroscopic shoulder surgery patients. The primary objective is to evaluate the efficacy of AZX100 based on the differences among three dosage groups in Patient and Observer Scar Assessment Scale (POSAS) scores at 12 months. Secondary objectives include safety determination and evaluations of efficacy via validated scar assessment scales using both 2D and 3D digital photography. One-hundred fifty (150) patients are now enrolled in the trial.
For more information: Capstone Therapeutics Announces Completion of Enrollment for AZX100 Phase 2 Clinical Trial in Dermal Scarring Following Shoulder